November 7, 2020, Lawrence, MA – Rubix LS has announced today that it is nearly halfway towards it funding goal of $1M, at $450,000, for its lead platform, StarSense, a virtual clinical trial platform that has been piloted in the utility of patient testing for...
Recently our Founder and CEO, Reginald Swift, sat down with the team at Pharma Tech Outlook magazine to discuss the changes happening with the pharma industry and how digital health, particularly virtual clinical trials are mobilizing access of pipeline therapeutics...
Rubix LS Successfully Isolated Protein Binding Receptors Previously in Ebola and Leishmaniasis, by Providing Real-Time Rapid Spectral Analysis of Key Proteins, is Actively Adapting Its Technology to Target Coronavirus WASHINGTON – Feb. 2,...
FOR IMMEDIATE RELEASE Rubix LS Continues 360 Degree Digital Health Campaign To Diversify Health Outcomes A respected leader in the life science and biotech product development and research sectors, Rubix LS has significantly boosted its growing digital healthcare...
